Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

Hepatology (Baltimore, Md.) - 1 Jul 2003

Poynard Thierry, Ratziu Vlad, McHutchison John, Manns Michael, Goodman Zachary, Zeuzem Stefan, Younossi Zobair, Albrecht Janice

Abstract excerpt

It has been suggested that hepatitis C virus (HCV) and especially genotype 3 is associated with steatosis. We assess the effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis. We analyzed 1,428 naïve patients included in a randomized trial. A single pathologist s...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol
Share to Drug Therapy, Combination
Share to Fatty Liver

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 12829989
DOI: 10.1053/jhep.2003.50267

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12829989-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.PMID 12829989Read ↗

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.Semantic proximity Read ↗

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients.Semantic proximity Read ↗

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.Semantic proximity Read ↗

Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.Semantic proximity Read ↗

Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.Semantic proximity Read ↗

Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.Semantic proximity Read ↗

Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3.Semantic proximity Read ↗

Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?Semantic proximity Read ↗

Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3.Semantic proximity Read ↗

Steatosis affects chronic hepatitis C progression in a genotype specific way.Semantic proximity Read ↗

PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.Semantic proximity Read ↗

Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.